The CD40/CD40 ligand (CD40L) costimulatory system, which amplifies immune responses and can induce inflammation, is believed to have a role in skin manifestations of other autoimmune diseases ...

One such molecule is the CD40L, which engages CD40 on dendritic and B cells of the immune system, enabling T cells to become activated as a result. Rodent studies using coreceptor blockade with ...

The safety and preliminary activity observed in this initial study of CD40L blockade in the prevention of GVHD supports further investigation of CD40 pathway modulation in the prevention and ...

Frexalimab is described by Sanofi as a ‘second-generation’ anti-CD40L antibody that can block the costimulatory CD40/CD40L cellular pathway necessary for adaptive and immune cell activation ...

Tonix Pharmaceuticals has reported positive topline outcomes from its Phase I single ascending dose study of its crystallisable fragment (Fc)-modified humanised anti-CD40 ligand (CD40L ...

Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that Steve Perrin, Ph.D., Chief Scientific Officer and President, will participate in a fireside chat at the upcoming Leerink ...

This trial demonstrates that next-generation CD40L blocking antibodies can be used safely in HCT recipients and supports initial clinical efficacy in the prevention of GVHD. Further study is needed in ...